{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:56:44Z","timestamp":1792450604482,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cmi.2024.08.021","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:29:35Z","timestamp":1724808575000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians"],"prefix":"10.1016","volume":"31","author":[{"given":"Valentina","family":"Galfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.08.021_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/cid\/ciy399","article-title":"National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010-2014","volume":"68","author":"Klein","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1473-3099(05)70243-7","article-title":"Meticillin-resistant Staphylococcus aureus","volume":"5","author":"Boyce","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0140-6736(09)61999-1","article-title":"Community-associated meticillin-resistant Staphylococcus aureus","volume":"375","author":"DeLeo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.08.021_bib4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jinf.2021.10.001","article-title":"Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study","volume":"83","author":"Willekens","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2024.08.021_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cmi.2022.10.019","article-title":"Impact of adherence to individual quality-of-care indicators on the prognosis of bloodstream infection due to Staphylococcus aureus: a prospective observational multicentre cohort","volume":"29","author":"Escrihuela-Vidal","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.08.021_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejim.2008.08.016","article-title":"Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians","volume":"20","author":"Falcone","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cmi.2024.08.021_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FTD.0000000000000942","article-title":"Therapeutic drug monitoring of antibiotics in critically ill patients: current practice and future perspectives with a focus on clinical outcome","volume":"44","author":"Koch","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cmi.2024.08.021_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000726","article-title":"\u0392-lactam therapeutic drug monitoring in critically ill patients: weighing the challenges and opportunities to assess clinical value","volume":"4","author":"Dilworth","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.cmi.2024.08.021_bib10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/14656566.2019.1675637","article-title":"Important new therapies for methicillin-resistant Staphylococcus aureus","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert OpinPharmacother"},{"key":"10.1016\/j.cmi.2024.08.021_bib11","first-page":"1222","article-title":"The current and future off-label uses of dalbavancin: a narrative review","volume":"27","author":"De Vito","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cmi.2024.08.021_bib12","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2024.08.021_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2334-13-370","article-title":"Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia","volume":"13","author":"Jung","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00134-019-05519-y","article-title":"Challenges in severe community-acquired pneumonia: a point-of-view review","volume":"45","author":"Torres","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2024.08.021_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119528","article-title":"Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia","volume":"10","author":"Falcone","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2024.08.021_bib17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib18","series-title":"Full prescribing information","year":"2016"},{"key":"10.1016\/j.cmi.2024.08.021_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.08.021_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2024.08.021_bib21","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1128\/AAC.01110-07","article-title":"Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib22","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2024.08.021_bib24","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/AAC.00144-09","article-title":"Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole","volume":"53","author":"Rodvold","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib25","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib26","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1128\/AAC.00712-11","article-title":"Penetration of vancomycin into epithelial lining fluid in healthy volunteers","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01726369","article-title":"Pulmonary disposition of vancomycin in critically ill patients","volume":"16","author":"Georges","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cmi.2024.08.021_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A\u00a010-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.cmi.2024.08.021_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijantimicag.2014.12.023","article-title":"Pharmacokinetic\/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function","volume":"45","author":"Canut","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jit129","article-title":"Effects of linezolid on suppressing in\u00a0vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia","volume":"208","author":"Diep","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijantimicag.2009.06.024","article-title":"Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection","volume":"34","author":"Yanagihara","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib35","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.athoracsur.2020.09.044","article-title":"Impact of infectious disease consultation on management and outcomes of infective endocarditis","volume":"112","author":"Okura","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cmi.2024.08.021_bib36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10096-022-04475-8","article-title":"Impact of therapeutic drug monitoring of antibiotics in the management of infective endocarditis","volume":"41","author":"Macheda","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib38","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2024.08.021_bib39","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2024.08.021_bib40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib41","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2024.08.021_bib42","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.08.021_bib43","first-page":"416","article-title":"Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis","volume":"34","author":"Boni","year":"2022","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib45","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob\u00a0Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib46","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"9","author":"Zasowski","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib47","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/jac\/dkad296","article-title":"Real-world experience of therapeutic drug monitoring and PK\/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria","volume":"78","author":"Fres\u00e1n","year":"2023","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib48","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40262-017-0623-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides","volume":"57","author":"Al Jalali","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.08.021_bib49","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/14787210.2021.1926986","article-title":"Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes","volume":"19","author":"Tiseo","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2024.08.021_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106749","article-title":"Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review","volume":"61","author":"Fazili","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107038","article-title":"Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections","volume":"63","author":"Cojutti","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib52","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/jac\/dkad331","article-title":"Dalbavancin plasma concentrations in 133 patients: a PK\/PD observational study","volume":"78","author":"Hervochon","year":"2023","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib53","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/antibiotics12111639","article-title":"Long-term suppressive therapeutic-drug-monitoring-guided dalbavancin therapy for cardiovascular prosthetic infections","volume":"12","author":"Gallerani","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.08.021_bib54","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13318-021-00705-0","article-title":"Serum and synovial vancomycin concentrations in patients with prosthetic joint infection after intra-articular infusion","volume":"46","author":"He","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.08.021_bib55","first-page":"165","article-title":"Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study","volume":"21","author":"Papadopoulos","year":"2009","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jiac.2015.11.012","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring","volume":"22","author":"Ashizawa","year":"2016","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106445","article-title":"Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib59","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/antibiotics11080996","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.08.021_bib60","article-title":"Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections","volume":"65","author":"Cojutti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib61","article-title":"A\u00a0descriptive case series of the relationship between maintenance of conservative PK\/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections","volume":"6","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00023-24","article-title":"Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular\/periprosthetic joint infections","volume":"68","author":"Cattaneo","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/antibiotics13010020","article-title":"Therapeutic drug monitoring of dalbavancin in real life: a two-year experience","volume":"13","author":"Cattaneo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.08.021_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study","volume":"7","author":"Van Hise","year":"2020","journal-title":"Drugs Real World Outcome"},{"key":"10.1016\/j.cmi.2024.08.021_bib65","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/antibiotics12101498","article-title":"The clinical efficacy of multidose oritavancin: a systematic review","volume":"12","author":"Baiardi","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.08.021_bib66","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A\u00a0two-dose oritavancin regimen using pharmacokinetic estimation analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs Real World Outcome"},{"key":"10.1016\/j.cmi.2024.08.021_bib68","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cid\/ciad386","article-title":"Daptomycin exposure as a risk factor for daptomycin-induced eosinophilic pneumonia and muscular toxicity","volume":"77","author":"Garreau","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.08.021_bib69","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.08.021_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jac\/dku337","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation","volume":"70","author":"Cojutti","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00228-024-03652-2","article-title":"The effects of drug-drug interaction on linezolid pharmacokinetics: a systematic review","volume":"80","author":"Xu","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2024.08.021_bib74","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/jac\/dkae188","article-title":"Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study","volume":"79","author":"Liu","year":"2024","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.08.021_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","article-title":"Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis","volume":"28","author":"Gatti","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2024.08.021_bib76","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2334-14-288","article-title":"How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:49:31Z","timestamp":1738450171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1198743X24004208"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.021","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}